BioAtla annual r&d spending
2019
2020
2021
2022
2023
2024
2025
BioAtla R&D Spending Growth & History (BCAB)
BioAtla's r&d spending was $43.6M for fiscal 2025.
View full BioAtla company overviewBioAtla annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $43.6M | −$19.5M | −30.94% |
| 2024 | 2024-12-31 | $63.1M | −$40.6M | −39.17% |
| 2023 | 2023-12-31 | $103.7M | $24.4M | +30.73% |
| 2022 | 2022-12-31 | $79.3M | $21.1M | +36.16% |
| 2021 | 2021-12-31 | $58.3M | $38.3M | +192.35% |
| 2020 | 2020-12-31 | $19.9M | −$6.0M | −23.10% |
| 2019 | 2019-12-31 | $25.9M | — | — |
BioAtla quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.3M | −$10.3M | −75.58% |
| Q1 2026 | 2026-03-31 | $4.6M | −$7.8M | −62.91% |
| Q4 2025 | 2025-12-31 | $8.0M | −$3.7M | −31.37% |
| Q3 2025 | 2025-09-30 | $9.5M | −$6.9M | −41.82% |
| Q2 2025 | 2025-06-30 | $13.7M | −$2.5M | −15.52% |
| Q1 2025 | 2025-03-31 | $12.4M | −$6.5M | −34.46% |
| Q4 2024 | 2024-12-31 | $11.7M | −$11.0M | −48.62% |
| Q3 2024 | 2024-09-30 | $16.4M | −$12.0M | −42.27% |
| Q2 2024 | 2024-06-30 | $16.2M | −$14.8M | −47.68% |
| Q1 2024 | 2024-03-31 | $18.9M | −$2.8M | −13.11% |
| Q4 2023 | 2023-12-31 | $22.7M | $800,000 | +3.66% |
| Q3 2023 | 2023-09-30 | $28.4M | $8.6M | +43.15% |
| Q2 2023 | 2023-06-30 | $31.0M | $10.2M | +49.49% |
| Q1 2023 | 2023-03-31 | $21.7M | $4.8M | +28.21% |
| Q4 2022 | 2022-12-31 | $21.9M | $5.4M | +32.99% |
| Q3 2022 | 2022-09-30 | $19.8M | $3.3M | +19.85% |
| Q2 2022 | 2022-06-30 | $20.7M | $5.9M | +39.47% |
| Q1 2022 | 2022-03-31 | $16.9M | $6.5M | +62.36% |
| Q4 2021 | 2021-12-31 | $16.4M | $6.0M | +56.87% |
| Q3 2021 | 2021-09-30 | $16.6M | $11.7M | +240.32% |
| Q2 2021 | 2021-06-30 | $14.8M | $11.9M | +408.04% |
| Q1 2021 | 2021-03-31 | $10.4M | $8.8M | +527.51% |
| Q4 2020 | 2020-12-31 | $10.5M | — | — |
| Q3 2020 | 2020-09-30 | $4.9M | — | — |
| Q2 2020 | 2020-06-30 | $2.9M | — | — |
| Q1 2020 | 2020-03-31 | $1.7M | — | — |
BioAtla r&d spending trends
Over the last five fiscal years, BioAtla's r&d spending increased from $19.9M to $43.6M, a change of $23.6M. The latest reported quarter, Q2 2026, shows $3.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioAtla source filings ↗